Circulation of the information to the Group by the Secretariat, evolution in the roles and methods of work for the RG

P.Kitching;T. Rendle and B. Newman

Appendix 30

Comparison of FMDV neutralization tests using three different cell lines: validation of the new FAO reference sera P. Moonen; G.K.W. Miedema; F. van Hemert-Kluitenberg; G. Chenard and A. Dekker

Appendix 31

Longevity of the antibody response in pigs and sheep following a single administration of high potency emergency FMD vaccines S.J. Cox and P.V. Barnett

Appendix 32

Enhancement of the immune response induced by the inclusion of saponin in oil adjuvanted vaccines against foot-and-mouth disease E. Smitsaart; N. Mattion; J.L. Filippi; B. Robiolo; O. Periolo; J. La Torre and R.C. Bellinzoni

Appendix 33

Experimental vaccination against FMDV with immunocomplexes H. Yadin; Dalia Chai; A. Bril; B. Gelman and M. Amadori

Appendix 34

Formaldehyde enhances BEI-inactivation rates of foot-and-mouth disease (FMD) virus by at least a ten-fold Simon J. Barteling and Nazeem I. Cassim

Appendix 35

Validating the efficacy of emergency foot-and-mouth disease vaccines in sheep following virus challenge using the non-structural polyprotein 3ABC MAT-ELISA Paul Barnett; Morag Forsyth and Sarah Cox

Appendix 36

Experimental FMD infections in pigs: a possible design for a PD50 experiment Hanny Swam and Aldo Dekker

Appendix 37

The second report of the European Pharmacopoeia Working Group. Present and future contacts with the European Pharmacopoeia and with EMEA Kris De Clercq (on behalf of the European Pharmacopoeia Working Group)

Appendix 38

Preliminary results from the EUFMD Expert Elicitation Workshop on risk of introduction of FMD to Europe John Ryan and Lisa Gallagher

Appendix 39

List of Participants